1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine | 666816-94-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(2-nitro-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-bromo-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine
• 英文别名: 8-Bromo-7-but-2-ynyl-3-methyl-1-[2-(2-nitrophenyl)-2-oxoethyl]purine-2,6-dione
• CAS: 666816-94-0
• 化学式: C₁₈H₁₄BrN₅O₅
• 分子量: 460.244
• InChiKey: XYEGHPDFRLKPOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  121
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：Himmelsbach Frank

  公开号：US20080255159A1

  公开（公告）日：2008-10-16

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 3 are defined as in claims 1 to 16 , the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药和盐具有有价值的药理特性，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。
• 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040097510A1

  公开（公告）日：2004-05-20

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPI-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R3的定义如权利要求1至16所述，其互变异构体、立体异构体、混合物、前药及其盐具有有价值的药理学特性，特别是对酶二肽基肽酶-IV（DPI-IV）的抑制作用。
• Xanthine derivatives, their preparation and their use in pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040166125A1

  公开（公告）日：2004-08-26

  Compounds of formula (I) 1 wherein R 1 to R 4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation, or calcitonin-induced osteoporosis using these compounds.

  公式（I）1的化合物，其中R1至R4的定义如权利要求中所述，或其前药或盐，特别是其生理上可接受的盐，含有这些化合物的制药组合物，以及使用这些化合物治疗I型和II型糖尿病、关节炎、肥胖症、移植排斥反应或降钙素诱导的骨质疏松症的方法。
• XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
  申请人：HIMMELSBACH Frank

  公开号：US20090131432A1

  公开（公告）日：2009-05-21

  Compounds of formula (I) wherein R 1 to R 4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation, or calcitonin-induced osteoporosis using these compounds.

  式(I)化合物，其中R1到R4的定义如权利要求书中所述，或其前药或盐，特别是其生理上可接受的盐，以及含有这些化合物的制药组合物，以及使用这些化合物治疗I型和II型糖尿病、关节炎、肥胖症、移植物排斥反应或降钙素诱导性骨质疏松症的方法。
• US7407955B2
  申请人：——

  公开号：US7407955B2

  公开（公告）日：2008-08-05